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Potential for alcohol and drug interactions in
older adults: evidence from the Irish longitudinal
study on ageing
Gráinne Cousins1,2*, Rose Galvin2, Michelle Flood1, Mary-Claire Kennedy3, Nicola Motterlini2, Martin C Henman3,
Rose-Anne Kenny4 and Tom Fahey2
Abstract
Background: Older adults are susceptible to adverse effects from the concomitant use of prescription medications
and alcohol. This study estimates the prevalence of exposure to alcohol interactive (AI) medications and
concomitant alcohol use by therapeutic class in a large, nationally representative sample of older adults.
Methods: Cross-sectional analysis of a population based sample of older Irish adults aged ≥60 years using data
from The Irish Longitudinal Study on Ageing (TILDA) (N = 3,815). AI medications were identified using Stockley’s
Drug Interactions, the British National Formulary and the Irish Medicines Formulary. An in-home inventory of
medications was used to characterise AI drug exposure by therapeutic class. Self-reported alcohol use was classified
as non-drinker, light/moderate and heavy drinking. Comorbidities known to be exacerbated by alcohol were also
recorded (diabetes mellitus, hypertension, peptic ulcer disease, liver disease, depression, gout or breast cancer), as
well as sociodemographic and health factors.
Results: Seventy-two per cent of participants were exposed to AI medications, with greatest exposure to
cardiovascular and CNS agents. Overall, 60% of participants exposed to AI medications reported concomitant
alcohol use, compared with 69.5% of non-AI exposed people (p < 0.001). Almost 28% of those reporting
anti-histamine use were identified as heavy drinkers. Similarly almost one in five, combined heavy drinking with
anti-coagulants/anti-platelets and cardiovascular agents, with 16% combining heavy drinking with CNS agents.
Multinomial logistic regression showed that being male, younger, urban dwelling, with higher levels of education
and a history of smoking, were associated with an increased risk for concomitant exposure to alcohol consumption
(both light/moderate and heavier) and AI medications. Current smokers and people with increasing co-morbidities
were also at greatest risk for heavy drinking in combination with AI medications.
Conclusions: The concurrent use of alcohol with AI medications, or with conditions known to be exacerbated by
alcohol, is common among older Irish adults. Prescribers should be aware of potential interactions, and screen
patients for alcohol use and provide warnings to minimize patient risk.
Keywords: Drug interactions, Alcohol interactive medications, Alcohol drinking/epidemiology, Aged
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Background
Older adults are susceptible to adverse effects from the
concomitant use of prescription medications and alcohol,
in part, because of changes in absorption, distribution and
metabolism of alcohol and other medications with age [1].
In addition to these physiological changes older adults have
reduced homeostatic capacity, and often take multiple
alcohol interactive (AI) medications [2-4]. The major
adverse clinical outcomes of medication-alcohol interactions
include raising blood alcohol levels, altering the metabolism
of drugs, liver toxicity, gastrointestinal inflammation and
bleeding, sedation, disulfiram-like-reactions, and interfer-
ence with the effectiveness of medications and exacerbating
their adverse effects [5,6]. For example, alcohol potentiates
the sedative effects of benzodiazepines, antidepressants
(e.g. tricyclics), anithisamines, muscle relaxants and opioids
[6], giving rise to falls, car accidents and death [7,8].
Nonsteroidal anti-inflammatory drugs (NSAIDs), when
combined with alcohol, can increase an older patients
risk for gastrointestinal bleeding [6]. A systematic review
has also indicated that alcohol consumption exacerbates
certain chronic conditions, such as liver disease, diabetes
mellitus, gastritis and other gastrointestinal conditions,
gout, depression, and breast cancer [9].
Although older adults typically report lower levels of
heavy drinking [5,10,11], many continue to engage in
patterns of alcohol consumption that exceed current
guidelines for older adults [11-15]. Despite being sus-
ceptible to adverse effects from the concomitant use of
AI medications and alcohol, few studies have considered
the potential for alcohol-drug interactions in older adults
[16,17]. One study found that 10% of older US adults were
at risk for potential adverse effects due to concomitant
use of alcohol and AI medications or conditions known to
be exacerbated by alcohol, this estimate increased to 26%
among current drinkers [18]. Another US study of com-
munity dwelling older adults identified 21.5% of current
drinkers as at-risk drinkers due to their alcohol use com-
bined with select comorbidities and 21.2% at-risk due to
their alcohol use combined with AI medications [12]. While
these studies provide prevalence estimates of the potential
risk for adverse effects due to concomitant use, specific pat-
terns of concomitant use are lacking [17]. Only one study
to date has considered the prevalence of alcohol use by
therapeutic class, with the most common combination of
alcohol and AI medications occuring with NSAIDs (20.2%),
antihistamines (20.1%) and anti-hypertensives (19.8%) [17].
These results relate to older US adults, which may differ
from European countries, as Europe reports the highest
per-capita alcohol consumption in the world with alcohol
related deaths among older Europeans increasing consider-
ably over the past ten years [19]. The purpose of this study
is to estimate the prevalence of AI medication exposure
and concomitant alcohol use by therapeutic class in a large,
nationally representative population sample of older
Irish adults. Additional objectives include: (i) the esti-
mation of the prevalence of concomitant alcohol use
with specific conditions known to deteriorate with alcohol
consumption [9]; and (ii) the identification of sociodemo-
graphic and health factors associated with concomitant
use of AI medications and alcohol.
Methods
Study population
This study was conducted in the context of The Irish
LongituDinal Study on Ageing (TILDA). TILDA recruited
a stratified clustered sample of 8,175 individuals, represen-
tative of the community dwelling population aged 50 years
and older in Ireland between October 2009 and February
2011. Wave 1 of the TILDA study included a face-to-face
interview in the participants’ home and a self-completion
questionnaire, which was returned after the visit. The ad-
justed response rate to the study was 62% and response to
the self-completion questionnaire was 84%. Full details of
the study sample and response rates have been described
elsewhere [20]. Home interviews were conducted by trained
professional social interviewers using Computer Assisted
Personal Interviewing (CAPI). Interviewers asked par-
ticipants in their homes “to record all medications that
you take on a regular basis, like every day or every week”,
and to provide medication packages to copy down the
correct medication names. Assistance from relatives
was permitted. Medications were coded using the World
Health Organization Anatomical Therapeutic Chemical
(ATC) classification system.
Participants also completed a self-completion question-
naire which explored issues considered particularly sensitive
for respondents to answer directly to an interviewer. The
self-completed questionnaire included items relating to al-
cohol consumption and the CAGE screening tool for prob-
lem drinking [21]. Participants aged 60 years and older who
responded to the alcohol items on the self-completion
questionnaire are included in the analysis. The study was
approved by the Faculty of Health Sciences Research Ethics
Committee at Trinity College Dublin and all participants
gave informed written consent.
Measures
Alcohol consumption
Current drinkers were defined as individuals who reported
drinking alcohol in the previous 6 months. The number of
drinks consumed per day/ per week was calculated using
self-reported quantity and frequency measures relating
to the past six months. Using the standard quantity-
frequency approach [22], participants were categorised as
non-drinkers, light/moderate drinkers, or heavier drinkers.
The National Institute on Alcohol Abuse and Alcoholism
(NIAAA) developed age specific guidelines, advising limits
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of no more than three drinks per day or seven drinks
per week for older men and women [23]. These limits
are based on a standard drink in the US, i.e. any drink
containing 14 grams of pure alcohol [23], and were were
amended to four drinks per day or ten drinks per week
given a standard drink in Ireland contains 10 grams of
pure alcohol [24,25]. Using the NIAA as a guideline, the
following thresholds were applied: heavier drinkers: in
excess of NIAA limits, light/moderate drinkers: less
than or up NIAA limits. Problem drinking was mea-
sured by the CAGE alcohol screening questionnaire
consisting of four items detailing whether the respond-
ent had ever 1) felt the need to cut down on their
drinking, 2) been criticised by others due to excessive
drinking, 3) felt bad or guilty due to drinking, or 4) had
a drink in the morning to steady their nerves, get rid of
a hangover or as an eye-opener. One point was allo-
cated for each positive response. Problem drinking was
defined as a score of ≥ 2. A cut point of ≥2 is associated
with 71% sensitivity and 91% specificity for problem
drinking in older adults [26].
Use of AI medications
Prescribed and OTC drugs which have the potential to
interact with alcohol were identified by Stockley’s Drug
Interactions [27], the British National Formulary (BNF)
[28] and the Irish Medicines Formulary (IMF) [29], as
specified alcohol interactivity and/or provided a cautionary
warning and/or recommendation for advisory labels. AI
medications were classified according to nine therapeutic
classes based on the BNF (cardiovascular agents; CNS
agents; antihistamines; anti-coagulants/anti-platelets;
antidiabetic agents; anti-infectives; gastrointestinal drugs;
immunomodulators; and muslce relaxants).
Medical conditions known to be exacerbated by alcohol,
as identified in a systematic review [9], were also recorded
during the interview. Participants were asked if they ever
received a diagnosis of diabetes mellitus, hypertension,
peptic ulcer disease, liver disease or breast cancer from
a doctor. Depressive symptoms, during the weeks before
interview, were also measured by the 20-item Center for
Epidemiologic Studies Depression (CES-D) scale [30].
Each symptom is scored on a scale from 0 (rarely or
none of the time, less than one day) to 3 (most or all of
the time, five-seven days) to give a possible total score
of 60. Depression was defined as a score of ≥16. A cut
point of ≥16 has 100% sensitivity and 88% specificity for
major depression in community dwelling older adults
[31]. Furthermore, prescription drugs for the treatment
of gout were used as proxies for gout (ATC, M04AA01).
A number of sociodemographic and health variables
were also recorded, including age, gender, urbanicity,
marital status, education, smoking status and self-reported
health status.
Data analysis
Statistical analyses were performed using STATA ver-
sion 13. All analyses were weighted with respect to age,
sex and education to ensure that data were nationally
representative. Chi square analyses were used to examine
the relationship between concomitant alcohol consumption
and use of AI medications by therapeutic class, to deter-
mine whether use of AI medications in certain thera-
peutic classes had any effect on alcohol consumption.
Additional analyses examined differences in drinking status
by therapeutic class.
Multinomial logistic regression was used to identify
factors associated with light/moderate, and heavier drink-
ing in older adults using one or more AI medications. In
this model, the outcome variable had 3 possible outcomes,
with individuals taking at least one AI medication and
not drinking alcohol (non-drinkers) as the reference cat-
egory. Interpretation of results for a specific risk factor
is based on the odds of being, for example, a heavier
drinker using AI medications rather than a non-drinker
using AI medications.
Results
Study population
3,815 adults over 60 years (mean age 69.7 ± 7.3, range
60–99 years) responded to alcohol items in the self-
completed questionnaire, with 2,490 (62.8%) reporting
alcohol consumption in the past 6 months. The preva-
lence of alcohol consumption declined with age, ran-
ging from 78% (60–64 years), 70% (65–69 years), 59%
(70–74 years), 55% (75–79 years) and 47% (80+ years).
Using the NIAA guidelines, 37.2% (n = 1,325) were classi-
fied as non-drinkers; 43.1% (n = 1,708) as light to moderate
drinkers; and 19.7% (782) were heavier drinkers (Table 1).
The proportion of older adults reporting heavy drinking
declined with age, however, one quarter of heavier drinkers
were aged 65–69 with 17% aged 70–74 years.
Problem drinking, defined by CAGE, was identified
in 8% of the total sample (12.7% of current drinkers).
The proportion of older adults with problem drinking
declined with age, ranging from 12% (60–64 years), 9%
(65–69 years), 7% (70–74 years), 4% (75–79 years) and
2% (80+ years). The prevalence of problem drinking
was higher among men (12.2% vs 4%), living in an
urban setting (10% vs 6%). Approximately, one in ten
adults with third level education reported problem
drinking (11%) compared to 7% of those with primary
or secondary education. The prevalence of problem
drinking was highest among participants who reported
being separated or divorced (17.5%). This compares to
approximately 9% among those who were married or
never married and 5% of those widowed. A higher pro-
portion of adults with depression (13% vs 8%), were
identified as problem drinkers.
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Alcohol interactive medications and alcohol consumption
Table 2 shows AI drug exposure by therapeutic class.
Almost three quarters (72%, n = 2,672) of all partici-
pants reported taking one or more AI medication, with
a mean and standard deviation of 2.04 ± 2. Exposure varied
by therapeutic class: cardiovascular agents (61.2%), CNS
agents (22.6%) and blood anti-platelets (31%). Table 2
also shows the prevalence of alcohol use by therapeutic
class. Sixty per cent of individuals using AI medications
were drinkers compared to 69.5% of those not using AI
medications (p <0.001). Individuals using AI medications
in the following classes, cardiovascular, CNS, blood
(anti-coagulant or anti-platelet) and antidiabetic, were
significantly less likely to report drinking alcohol. Yet,
more than half of those exposed to cardiovascular, CNS,
blood or antidiabetic agents reported concurrent alcohol
consumption. Table 2 also shows that the prevalence of
alcohol use in combination with select conditions was
high, particularly for those reporting gout (74.5%) and
hypertension (65%).
Further analysis of drinking status among AI drug
users by therapeutic class are presented in Figure 1. More
than a quarter of those reporting antihistamine use were
identified as heavier drinkers. Similarly, almost one in five
older adults combined heavy drinking with cardiovascular
agents, blood (anti-coagulant or anti-platelet) and antidia-
betic agents, with 16% combining heavy drinking with CNS
agents. Thirteen per cent of people taking anti-epileptics,
Table 1 Characteristics of study population (N = 3,815)
Characteristics Nondrinker
(n = 1,325)
Light-moderate drinker
(n = 1,708)
Heavier drinker
(n = 782)
Total (N = 3,815)
Gender
Male 494 (36.0) 714 (43.2) 566 (73.8) 1,774 (46.6)
Female 831 (64.0) 994 (56.8) 216 (26.2) 2,041 (53.4)
Age
60-64 246 (19.5) 576 (36.2) 295 (42.9) 1,117 (31.3)
65-69 292 (19.6) 463 (24.3) 210 (24.5) 965 (22.6)
70-74 314 (21.2) 294 (15.6) 148 (16.8) 756 (17.9)
75-79 241 (19.7) 217 (13.8) 73 (9.0) 531 (15.0)
80+ 231 (20.0) 155 (10.2) 55 (6.8) 441 (13.2)
Residence
Rural 743 (58.3) 787 (48.1) 280 (37.4) 1,810 (49.7)
Urban 578 (41.8) 919 (52.0) 501 (62.6) 1998 (50.3)
Marital status
Married 777 (56.1) 1,189 (69.5) 565 (71.3) 2,531 (64.9)
Widowed 350 (29.7) 309 (19.3) 116 (15.3) 775 (22.4)
Divorced/separated 46 (3.2) 66 (3.6) 49 (6.1) 161 (4.0)
Never married 152 (11.1) 144 (7.5) 52 (7.3) 348 (8.8)
Education level
None/primary level 630 (58.3) 511 (39.1) 225 (37.1) 1,366 (45.9)
Secondary level 449 (31.9) 641 (40.9) 285 (40.4) 1,375 (37.4)
Third level 246 (9.8) 554 (20.0) 272 (22.5) 1,072 (16.7)
Self-reported health status
Excellent to very good 687 (50.8) 994 (56.7) 439 (54.1) 2,120 (54.0)
Good 392 (29.7) 495 (29.6) 242 (31.9) 1,129 (30.1)
Fair to poor 241 (19.5) 217 (13.8) 101 (14) 559 (15.9)
Depression (CES-D ≥16) 109 (8.9) 116 (7.2) 50 (6.7) 275 (7.7)
Smoking history
Current smoker 166 (13.2) 207 (12.8) 140 (19.6) 513 (14.3)
Past smoker 439 (33.2) 730 (43.2) 413 (51.1) 1,582 (41.0)
Never smoked 720 (53.6) 771 (44) 229 (29.3) 1,720 (44.7)
Note: Totals may not equal 100% because of rounding.
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Table 2 Alcohol-Interactive (AI) medication exposure, morbidity and prevalence of alcohol use by therapeutic class and
morbidity (N = 3,815)
Characteristics Exposure to
AI medications
Alcohol use in individuals
using AI medications in class
Alcohol use in individuals not
using AI medications in class
Total
% % % P-value
Cardiovascular agents 61.2 60.4 67.0 <0.001
Angiotensin-receptor blockers & combinations 32.9 60.8 64.0 0.07
Beta blockers & combinations 19.5 57.5 64.3 0.001
Calcium channel blockers & combinations 13.7 57.8 63.8 0.01
Diuretics 12.5 53.5 64.3 <0.001
Alpha blockers 2.9 60.2 63.0 0.57
Vasodilator Antihypertensives 0.5 73.0 62.9 0.36
Nitrates 2.7 59.0 63.1 0.44
Cholesterol lowering agents 36.7 63.2 62.8 0.84
CNS agents 22.6 53.5 65.7 <0.001
NSAID 1.9 59.4 63.0 0.59
COX2 inhibitors 1.5 62.4 62.9 0.93
Opioid analgesics 3.1 51.8 63.3 0.02
Non-opioid analgesics 5.3 54.6 63.4 0.03
Anti-epileptics 2.8 50.2 63.3 0.008
Hypnotics 5.5 54.7 63.4 0.02
Anxiolytics 2.7 44.1 63.5 <0.001
Barbiturates -
Antipsychotics 0.9 43.2 63.1 0.03
Antidepressants 7.4 52.9 63.8 0.002
Stimulants - - -
Nausea and Vertigo 1.9 46.8 63.3 0.01
Antimigraine - - -
Antiparkinson drugs 0.6 57.6 63.0 0.60
Dopaminergics 0.18 84.8 62.9 0.25
Drugs for dementia 0.46
Drugs for dependence -
Antihistamines 0.9 66.9 62.9 0.65
Sedating 0.13 63.0 63.0 0.99
Non-sedating 0.84 65.0 62.9 0.82
Blood 34.2 58.5 65.3 <0.001
Anti-coagulant 3.6 55.9 63.2 0.09
Anti-platelet 31.0 58.8 64.8 0.001
Antidiabetic agents 7.2 53.8 63.7 0.002
Anti-infectives 0.2 47.0 63.0 0.43
Gastrointestinal drugs 1.2 49.5 63.1 0.09
Immunomodulators 1.0 50.7 63.1 0.10
Muscle relaxants 0.2 80.3 62.9 0.28
Other 3.0 69.6 62.8 0.18
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antipsychotics or hypnotics reported heavy drinking, with
18% of those taking antidepressants also reporting heavy
drinking. Furthermore, approximately one in five older
adults with diabetes, hypertension, peptic ulcer, or depres-
sion, were identified as heavy drinkers. Individuals with
breast cancer were least likely to report heavy drinking
(9.6%). In contrast, almost 43% of older adults with gout
reported heavy drinking (Figure 1).
Results from the multinomial model are presented in
Table 3. These results show consistency across a num-
ber of factors discriminating between various levels of
concomitant use of alcohol with AI medications. Being
male, younger, urban dwelling, better educated, never
married and having a history of smoking distinguished
drinkers at both levels from non-drinkers. Additional
factors predicting heavy drinking in combination with
Table 2 Alcohol-Interactive (AI) medication exposure, morbidity and prevalence of alcohol use by therapeutic class and
morbidity (N = 3,815) (Continued)
Morbidity Prevalence
of condition
Alcohol use in individuals
with condition
Alcohol use in individuals
without condition
% % % P-value
Diabetes 9.5 52.5 63.9 < 0.001
Hypertension 47.7 65.0 67.3 0.22
Peptic ulcer 7.1 60.8 63.0 0.49
Gout 1.9 74.5 62.7 0.08
Depression(CES-D ≥16) 7.7 57.7 63.5 0.06
Liver disease 0.54 39.7 62.9 0.04
Breast cancer 2.3 63.8 62.8 0.86
Figure 1 Drinking status by exposure to AI medications and morbidity (N = 3,815).
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AI medications included being a current smoker, and
increasing co-morbidities. In contrast, increasing numbers
of AI medications and fair to poor health were associated
with a reduced odds of heavy drinking in combination
with AI medications relative to non-drinkers.
Discussion
In this large, population-based sample of older people, 72%
were exposed to at least one AI medication, with exposure
varying by therapeutic class. Of those exposed to AI medi-
cations, 60% reported concomitant alcohol use, increasing
their risk for alcohol related adverse reactions. This is in
contrast to a large community based US study in adults of
similar ages in which 20% of those on AI medications re-
ported alcohol use [17]. The prevalence of alcohol use
across each of the therapeutic classes was also larger in this
study relative to the US study [17]. For example, we found
that 53.5% of people using CNS agents concurrently drink
alcohol, compared to 20.2% of older American adults.
This may be due to a lower prevalence of self- reported
alcohol consumption in the US study, 20.3% compared
to 62.3% of older Irish adults. It is plausible that a
Table 3 Results of multinomial logistic model of light-moderate, and heavier drinking combined with Alcohol Interactive
(AI) medications (N = 2,672)
Light-Moderate drinker/nondrinker + AI Heavier drinker/nondrinker + AI
Characteristics OR (95% CI) P value OR (95% CI) P value
Gender
Male 1.00 1.00
Female 0.75 (0.61 - 0.92) 0.006 0.18 (0.14 - 0.24) <0.001
Age
60-64 1.00 1.00
65-69 0.80 (0.61 - 1.07) 0.13 0.64 (0.45 - 0.92) 0.02
70-74 0.46 (0.34 - 0.63) <0.001 0.40 (0.27 - 0.59) <0.001
75-79 0.50 (0 .36 - 0.69) <0.001 0.25 (0.16 - 0.39) <0.001
80+ 0.38 (0.27 - 0.54) <0.001 0.22 (0.13 - 0.35) <0.001
Residence
Rural 1.00 1.00
Urban 1.48 (1.22 - 1.80) <0.001 2.36 (1.80 - 3.08) <0.001
Marital status
Married 1.00 1.00
Never married 0.49 (0.35 - 0.69) <0.001 0.48 (0 .30 - 0.75) 0.001
Widowed 0.85 (0.66 - 1.10) 0.22 1.12(0.78 - 1.59) 0.54
Divorced/separated 0.57 (0.34 - 0.95) 0.03 0.83 (0.45 - 1.50) 0.53
Education level
None/primary level 1.00 1.00
Secondary level 1.41 (1.13 - 1.76) 0.002 1.91 (1.45 - 2.53) <0.001
Third level 2.04 (1.60 - 2.61) <0.001 3.07 (2.23 - 4.24) <0.001
Self-reported health status
Excellent to very good 1.00 1.00
Good 1.12 (0.89 - 1.39) 0.33 1.12 (0.85 - 1.48) 0.42
Fair to poor 0.84 (0.63 - 1.12) 0.23 0.68 (0.46 - 0.98) 0.04
Depression (CES-D ≥16) 0.96 (0.79 - 1.16) 0.70 0.86 (0.68 - 1.09) 0.21
Smoking history
Never smoked 1.00 1.00
Current smoker 1.09 (0.81 - 1.47) 0.57 2.65 (1.79 – 3.93) <0.001
Past smoker 1.52 (1.23- 1.89) <0.001 2.07 (1.53 - 2.78) <0.001
Number of AI drugs 0.95 (0.90 - 1.00) 0.09 0.91 (0.85 - 0.98) 0.018
Number of co-morbidities 1.04 (0.94 - 1.15) 0.49 1.29 (1.12 - 1.47) <0.001
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higher proportion of older Irish adults drink alcohol,
thereby increasing their potential risk for alcohol related
adverse reactions. Furthermore, 8% of the current sample,
(12.7% of current drinkers), were identified as problem
drinkers on the CAGE screening questionnaire, which
is higher than previous studies of older people [13,19].
Some of these differences may be explained by our younger
cohort (60 years and older), however this is unlikely to
account for the total variation as, although the prevalence
of alcohol consumption declined with age, it remained rela-
tively high among our older age-groups.
Although exposure to AI medications varied by thera-
peutic class, an examination of concurrent alcohol use
suggests consistency across therapeutic classes. Concurrent
alcohol use ranged between approximately 50-60% for most
therapeutic classes, with the exception of muscle relaxants
(80%). Similarly, heavy drinking was identified in approxi-
mately one in five older adults reporting concurrent use of
cardiovascular, blood and anti-diabetic agents. The concur-
rent use of psychotropics with heavy alcohol consumption
is of particular concern, as they may cause the most dan-
gerous alcohol related adverse drug reactions [8]. Sixteen
percent of older adults taking CNS agents were identified
as heavy drinkers; 14.8% of people taking opioid analgesics
reported heavy drinking. Similarly, 13% of people taking
anti-epileptics, antipsychotics or hypnotics reported heavy
drinking, with almost one in five of those taking antide-
pressants also reporting heavy drinking. This is consistent
with other studies, which suggest that concurrent use of
psychotropic drugs and alcohol has become more preva-
lent in older adults [32-34]. However, this may be an arte-
fact of increased use of psychotropic medications with
age. We also found a high prevalence of alcohol consump-
tion among people with conditions known to be exacer-
bated by alcohol consumption.
Although we are unable to ascertain the reasons behind
alcohol consumption, particularly heavy consumption,
in combination with AI medications, previous research
has shown that many older adults are often unaware of
the potential risk [35]. This may be compounded by
the fact that older people are less likely to reveal a his-
tory of excessive alcohol consumption [36], and health-
care workers have a lower degree of suspicion when
assessing older people [37]. In light of these findings,
general practitioners should take the opportunity to review
their patients’ alcohol consumption prior to prescrib-
ing AI medications. Knowing how much alcohol their
older patients are drinking would facilitate an effective
assessment of risk, and identify those patients in need of
counselling in relation to the safe use of alcohol and medi-
cations. Counselling patients on long-term AI medications
is particularly important, as it may be easier to abstain
from alcohol if concomitant medications are for defined
short time periods compared to long-term medications.
Pharmacists are also in a position to educate patients
in relation to the potential risk associated with alcohol
consumption and AI medication at the point of dispensing
AI medications.
Limited clinican time for alcohol screening highlights
the need to prioritise high-risk groups. Findings from the
present study suggest that younger, better educated men,
with a history of smoking and living in a city are at greatest
risk. One positive finding was a 9% reduction in the
odds of alcohol consumption among heavy drinkers with
each additional AI drug taken. This is consistent with the
US study [17]. In contrast, those with increasing numbers
of co-morbitities, known to worsen with alcohol, were
significantly more likely to engage in heavy drinking.
This may represent a coping strategy.
When interpreting our findings, the following limitations
should be considered. A number of medical conditions,
and drinking frequency and quantity were based on self-
report, which may result in misclassification bias. However,
evidence suggests that self-reported alcohol consumption is
both reliable and valid [38]. Furthermore, although this
study identifies a number of risk factors that increase
older peoples’ risk of exposure to alcohol-drug interactions,
we do not have information on the drug strength, dose
or duration or on the consequences or severity of these
interactions. Further study of this cohort is necessary to
quantify adverse outcomes associated with concomitant
use of AI medications and alcohol.
Furthermore, the finding that alcohol consumption
declines with age may represent a survival bias, with
heavy drinkers either dying or stopping their alcohol at
an earlier age. Future longitiudinal analysis is necessary
to determine whether this age related decline remains
with advancing age, as research has found that the average
amount of alcohol consumed by older people who con-
tinue to drink does not change over time [39].
Conclusions
In conclusion, these findings indicate that many Irish older
adults drink in excess of the recommended limits for their
age, with many using alcohol in combination with alcohol
interactive medications or conditions known to be exacer-
bated with alcohol intake. As the proportion and age of the
older population continues to increase, the absolute num-
ber using AI medications will also increase. This increase in
the prevalence of AI medications, combined with increased
use of alcohol suggests the proportion of older adults at risk
of alcohol related adverse drug events will increase in future
years [17]. These findings highlight the importance of
patient education to ensure older adults understand the
potential risks associated with their combined alcohol and
medication use. Prescribers should also be aware of the
potential interactions, and screen patients for alcohol use
and provide warnings to minimize patient risk.
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